Health
Eli Lilly’s Stock Has Swung on Alzheimer’s Drug Developments. What Investors Need to Know. – Barron’s
Eli Lilly may have recently disappointed investors with a study’s data, but the approach being taken by it and other drugmakers to treat the disease seems to be…
When
Eli Lilly
presented the results of a small study of its Alzheimers disease therapy donanemab last weekend, investors were hoping for a miracle. It didnt materialize, and Lilly (ticker: LLY) shares, which had run up 11.7% when the company previewed the study back in January, slid 11.6% by the end of trading on Thursday.Those swings in the stock dont tell the real story of donanemab. The data that Lilly presented last Saturday were positive for Alzheimers drug development in general, and for…
-
Noosa News23 hours agoHomicide investigation launched into stabbing death of 39-year-old Brisbane man at Bowen Hills apartment
-
General22 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
Noosa News5 hours agoLune Has Launched a Loyalty Program to Reward Your Love of World-Famous Croissants and Other Tasty Pastries
-
Noosa News21 hours agoAll this country music is giving me the honky-tonk blues